Sundus Yahya1, Lubna Bhatt2, Margaret King2, Sarah Pirrie3, Ruth Wyatt4, Muhammed Suhail Anwar4, Ahmed El-Modir4, Indrajit Fernando4. 1. Hall Edwards Radiotherapy Research group, Cancer Centre, Queen Elizabeth Hospital, Birmingham, U.K. drsundusyahya@yahoo.co.uk. 2. Christie Hospital, Manchester, U.K. 3. Cancer Research UK Clinical Trials Unit, Institute for Cancer Studies, The University of Birmingham, Birmingham, U.K. 4. Hall Edwards Radiotherapy Research group, Cancer Centre, Queen Elizabeth Hospital, Birmingham, U.K.
Abstract
AIM: We report on outcomes and significant grade 3-4 late toxicities between January 1999 and October 2006 following introduction of multi-phase treatment and effect of shielding in treatment of cervical cancer with concurrent chemoradiation. PATIENTS AND METHODS: Radiotherapy dose by phase, recurrence, survival and toxicity data was collated by a retrospective review of clinical notes. Shielding information was retrieved from original planning films. RESULTS: 3-year survival for stages I, II and III disease were 89%,76% and 51% respectively. Local pelvic failure was 9%. Overall significant late toxicity (SLT) rate was 13%, with lower rates for post-operative treatment than primary chemoradiation (4% vs. 16%). SLT with single phase treatment was 29% versus 12% following multiphase EBRT and 16% when <2 areas were shielded versus 6% with ≥3 shielded areas (p=0.01). CONCLUSION: Shielding and multi-phase treatment not only reduce dose to organs at-risk but can also reduce late toxicity without compromising local control or survival. Copyright
AIM: We report on outcomes and significant grade 3-4 late toxicities between January 1999 and October 2006 following introduction of multi-phase treatment and effect of shielding in treatment of cervical cancer with concurrent chemoradiation. PATIENTS AND METHODS: Radiotherapy dose by phase, recurrence, survival and toxicity data was collated by a retrospective review of clinical notes. Shielding information was retrieved from original planning films. RESULTS: 3-year survival for stages I, II and III disease were 89%,76% and 51% respectively. Local pelvic failure was 9%. Overall significant late toxicity (SLT) rate was 13%, with lower rates for post-operative treatment than primary chemoradiation (4% vs. 16%). SLT with single phase treatment was 29% versus 12% following multiphase EBRT and 16% when <2 areas were shielded versus 6% with ≥3 shielded areas (p=0.01). CONCLUSION: Shielding and multi-phase treatment not only reduce dose to organs at-risk but can also reduce late toxicity without compromising local control or survival. Copyright
Authors: Huyen Thi Phung; Minh Cong Truong; Long Thanh Nguyen; Anh Thi Van Dang; Thanh Ha Vu; Hoa Thi Nguyen Journal: Asian Pac J Cancer Prev Date: 2021-03-01